United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,274 shares of United Therapeutics Corporation stock in a transaction dated Thursday, September 21st. The stock was sold at an average price of $116.07, for a total value of $147,873.18. Following the transaction, the chief executive officer now directly owns 2,343 shares in the company, valued at $271,952.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Corporation (NASDAQ UTHR) opened at 114.60 on Monday. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The firm has a market cap of $4.98 billion, a price-to-earnings ratio of 13.29 and a beta of 1.52. The company has a 50 day moving average price of $128.37 and a 200-day moving average price of $129.08.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of $3.61 by ($4.86). The company had revenue of $444.60 million during the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.42 EPS. Equities research analysts anticipate that United Therapeutics Corporation will post $10.09 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/25/insider-selling-united-therapeutics-corporation-uthr-ceo-sells-147873-18-in-stock.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Boston Partners acquired a new position in United Therapeutics Corporation in the first quarter valued at about $582,000. US Bancorp DE grew its stake in United Therapeutics Corporation by 5.9% in the first quarter. US Bancorp DE now owns 4,047 shares of the biotechnology company’s stock valued at $548,000 after acquiring an additional 225 shares during the period. World Asset Management Inc grew its stake in United Therapeutics Corporation by 9.9% in the first quarter. World Asset Management Inc now owns 2,885 shares of the biotechnology company’s stock valued at $391,000 after acquiring an additional 261 shares during the period. Sei Investments Co. grew its stake in United Therapeutics Corporation by 7.0% in the first quarter. Sei Investments Co. now owns 30,238 shares of the biotechnology company’s stock valued at $4,093,000 after acquiring an additional 1,975 shares during the period. Finally, Quantbot Technologies LP acquired a new position in United Therapeutics Corporation in the first quarter valued at about $403,000.

A number of research firms recently issued reports on UTHR. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a report on Friday, July 14th. ValuEngine lowered United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. UBS AG reaffirmed a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a report on Thursday, July 6th. BidaskClub raised United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, June 9th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. Six equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $134.50.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.